Darzalex Faspro market seen growing on cancer cases and outpatient care shift

The Darzalex Faspro market is expanding as multiple myeloma diagnoses rise and oncology care moves toward faster, outpatient treatments. A new Business Research Company report says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Darzalex Faspro’s market growth tracks broader demand for multiple myeloma treatments that are faster, easier to administer and better suited to outpatient oncology care. - Rising cancer incidence and expanding healthcare infrastructure are increasing the pool of patients who can access subcutaneous cancer therapies. - The report frames Darzalex Faspro as part of a wider shift toward CD38-targeted and subcutaneous oncology treatments.

What happened: - The Business Research Company published its Darzalex Faspro Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says North America held the largest share of the Darzalex Faspro market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Darzalex Faspro treats multiple myeloma by targeting and eliminating CD38-positive cells. - Darzalex Faspro is administered as a subcutaneous injection, unlike traditional intravenous infusions. - The report links prior market growth to the clinical success of daratumumab, limits of intravenous infusions, rising multiple myeloma prevalence, wider hospital oncology adoption and improved patient survival rates. - Expected growth drivers include more multiple myeloma diagnoses, a shift toward outpatient oncology care, preference for shorter administration times, ongoing clinical trials and favorable reimbursement policies. - Reported trends include stronger use of subcutaneous oncology therapies, broader CD38-targeted treatment adoption, faster drug delivery methods, more treatment options for multiple myeloma and better patient convenience. - The report ties broader cancer market growth to aging populations, unhealthy lifestyle habits, environmental risks, improved detection and genetic factors. - The American Cancer Society reported in April 2024 that 2022 saw 20 million new cancer cases and 9.7 million deaths worldwide. - The American Cancer Society projects new cancer diagnoses could rise to 35 million by 2050. - The report says global healthcare infrastructure expansion is supporting outpatient administration of Darzalex Faspro. - The American Health Care Association reported in May 2023 that the United States had 6,129 hospitals, up 0.591% from 6,093 the year before.

Between the lines: - The market story is less about one drug alone and more about the oncology system moving toward treatments that reduce infusion time and hospital burden. - North America’s lead suggests early access, advanced infrastructure and faster adoption of innovative therapies remain competitive advantages. - Asia-Pacific’s growth outlook points to where future demand expansion may be concentrated as diagnosis rates and treatment access improve.

What's next: - The report says future demand should be lifted by continued multiple myeloma diagnosis growth and broader outpatient oncology use. - Ongoing clinical trials and reimbursement support could help sustain adoption across more markets. - The Business Research Company added 2026 report features including TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - More information is available from The Business Research Company.

The bottom line: - Darzalex Faspro’s market momentum is being driven by the broader shift to faster, subcutaneous cancer care as multiple myeloma cases rise worldwide.